FX 322

Drug Profile

FX 322

Alternative Names: FX-322

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Frequency Therapeutics
  • Class Small molecules
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sensorineural hearing loss

Most Recent Events

  • 30 May 2017 Phase-I clinical trials in Sensorineural hearing loss in Australia (Intratympanic) (ACTRN12617000704392)
  • 28 Mar 2017 Frequency Therapeutics plans a phase I trial for Sensorineural hearing loss in Australia (ACTRN12617000704392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top